- Home
- HE vs NRIX Comparison
HE vs NRIX Comparison
Compare HE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HE
- NRIX
- Stock Information
- Founded
- HE 1891
- NRIX 2009
- Country
- HE United States
- NRIX United States
- Employees
- HE N/A
- NRIX N/A
- Industry
- HE Electric Utilities: Central
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- HE Utilities
- NRIX Health Care
- Exchange
- HE Nasdaq
- NRIX Nasdaq
- Market Cap
- HE 2.0B
- NRIX 1.7B
- IPO Year
- HE N/A
- NRIX 2020
- Fundamental
- Price
- HE $11.79
- NRIX $17.21
- Analyst Decision
- HE Hold
- NRIX Strong Buy
- Analyst Count
- HE 3
- NRIX 14
- Target Price
- HE $11.25
- NRIX $26.50
- AVG Volume (30 Days)
- HE 2.0M
- NRIX 1.6M
- Earning Date
- HE 11-07-2025
- NRIX 10-09-2025
- Dividend Yield
- HE N/A
- NRIX N/A
- EPS Growth
- HE N/A
- NRIX N/A
- EPS
- HE 0.09
- NRIX N/A
- Revenue
- HE $3,080,252,000.00
- NRIX $83,687,000.00
- Revenue This Year
- HE $12.58
- NRIX $58.48
- Revenue Next Year
- HE $2.10
- NRIX N/A
- P/E Ratio
- HE $18.15
- NRIX N/A
- Revenue Growth
- HE 3.28
- NRIX 48.32
- 52 Week Low
- HE $8.14
- NRIX $8.18
- 52 Week High
- HE $13.41
- NRIX $23.00
- Technical
- Relative Strength Index (RSI)
- HE 56.47
- NRIX 79.85
- Support Level
- HE $11.09
- NRIX $16.63
- Resistance Level
- HE $11.88
- NRIX $17.65
- Average True Range (ATR)
- HE 0.31
- NRIX 1.00
- MACD
- HE 0.02
- NRIX 0.42
- Stochastic Oscillator
- HE 91.98
- NRIX 92.98
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.